Thomas Cyberski

Thomas Cyberski

Auto-generated profile, based on publicly available information

Thomas Cyberski

Department of Otolaryngology–Head and Neck Surgery Rush University Medical Center Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
TCThomas F. Cyberski
Thomas F. Cyberski
ASAlka Singh
Alka Singh
MKMichael Korzinkin
Michael Korzinkin
VMVasudha Mishra
Vasudha Mishra
FPFrank W. Pun
Frank W. Pun
ARAri J. Rosenberg
Ari J. Rosenberg
The proto-oncogene MYC encodes a nuclear transcription factor that has an important role in a variety of cellular processes, such as cell cycle progression, proliferation, metabolism, adhesion, apoptosis, and therapeutic resistance. MYC amplification is consistently observed in aggressive forms of several solid malignancies and correlates with poor prognosis and distant metastases. While the tumorigenic effects of MYC in patients with head and neck squamous cell carcinoma (HNSCC) are well known, the molecular mechanisms by which the amplification of this gene may confer treatment resistance, especially to immune checkpoint inhibitors, remains under-investigated. Here we present a unique case of a patient with recurrent/metastatic (R/M) HNSCC who, despite initial response to nivolumab-based treatment, developed rapidly progressive metastatic disease after the acquisition of MYC amplification. We conducted comparative transcriptomic analysis of this patient’s tumor at baseline and upon progression to interrogate potential molecular processes through which MYC may confer resistance to immunotherapy and/or chemoradiation and used TCGA-HNSC dataset and an institutional cohort to further explore clinicopathologic features and key molecular networks associated with MYC amplification in HNSCC. This study highlights MYC amplification as a potential mechanism of immune checkpoint inhibitor resistance and suggest its use as a predictive biomarker and potential therapeutic target in R/M HNSCC.

1 July 2025 in OTO Open
Verified
Journal Article
Open access
RWRussell A. Whitehead
Russell A. Whitehead
AMAbdel R. Metwally
Abdel R. Metwally
EPEvan A. Patel
Evan A. Patel
TCThomas Cyberski
Thomas Cyberski
RPRobin Powszok
Robin Powszok
PBPete S. Batra
Pete S. Batra
Objective: Literature describing disparities in chronic rhinosinusitis (CRS) often analyzes race, gender, or socioeconomic status (SES) in isolation. Analyses encompassing a comprehensive range of disparities remain lacking. We conducted a systematic review to provide a detailed characterization of the CRS disparity landscape.Data Sources: A systematic review was conducted in Covidence adhering to Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. A search of PubMed/MEDLINE, CINAHL, Scopus, etc. was performed for literature published through September 2024.Review Methods: A total of 690 publications were identified and screened by two authors independently. In total, 26 ultimately met the inclusion criteria. Studies were classified by pertaining health disparity (race, gender, SES, age, and geographic region) and reported outcomes (incidence, severity, and treatment choice).Results: In total, 26 studies on CRS disparities were published from 2012 to 2024. 16 focused on SES, describing that lower SES was associated with reduced treatment adherence, resulting in poorer endoscopic findings and quality of life. 14 studies examined racial/ethnic disparities. Hispanic patients were more symptomatic than non‐Hispanic patients, whereas black patients had fewer health visits, leading to worse outcomes. Other studies discussed the impact of gender, age, and/or geographic region (n = 9, 4, 4, respectively). Findings included higher symptom burden among female patients and higher CRS incidence in regions of air pollution. Only three studies proposed solutions to disparities.Conclusion: Most literature on CRS disparities describes the influence of SES and race on disease presentation and progression. Other disparities related to gender, age, and geographic region were identified. Further research should uncover root causes and propose detailed solutions to advance equitable care in CRS.

1 January 2023 in OTO Open
Verified
Journal Article
Open access
TCThomas Cyberski
Thomas Cyberski
STSwetha Tatineni
Swetha Tatineni
ASAndrea Shogan
Andrea Shogan
FBFuad M. Baroody
Fuad M. Baroody
Objective: To assess the availability and uniformity of application information for away subinternships and survey 4th‐year medical students on their experiences obtaining away subinternships in otolaryngology‐head and neck surgery (OHNS) during the 2022 to 2023 application cycle.Study Design: Cross‐sectional study.Setting: Online survey.Methods: The Association of American Medical College's Visiting Student Learning Opportunities (VSLO) program was queried for information on OHNS away subinternship applications. A survey assessing 4th‐year medical students' perceptions of the away subinternship application process was distributed via OHNS residency program directors and Otomatch.Results: Of 129 OHNS residency programs, 103 (80%) offered away subinternship opportunities on VSLO. Variability in application release dates (January 18 to June 3, 2022), offer release dates (January 27 to August 7, 2022), and estimated cost ($22‐$5500) were found. The most common application requirements were a transcript (98.1%) and a CV/resume (90.3%). There were 64 survey respondents, for a 13% response rate. The most common concerns include applying to too few programs (80%) and not knowing offer release dates (77%). The most common stressors include choosing a number of programs to which to apply (48%) and cost (35%). The majority (76%) reported difficulty finding updated information on program websites. Among the proposed changes, the greatest support was found for having all applications on VSLO (88%), uniform application release date (84%), and uniform application requirements (82%).Conclusion: The OHNS away subinternship application process is a significant source of anxiety for medical students due to the tremendous variability in application and acceptance procedures. Having all applications on VSLO, uniform application requirements, and uniform application opening and offer release dates would better facilitate this process.

1 January 2024 in OTO Open
Verified
Journal Article
Open access
TCThomas F. Cyberski
Thomas F. Cyberski
AWAlexander Z. Wang
Alexander Z. Wang
BBBrandon J. Baird
Brandon J. Baird
Objective: The aim of this study is to evaluate the association between race and the treatment of laryngeal dysplasia and early‐stage laryngeal squamous cell carcinoma (LSCC).Study design: Retrospective Cohort Study.Setting: Large multispecialty academic medical center.Methods: Patients were treated for laryngeal dysplasia or LSCC between September 2019 and September 2022. A retrospective chart review was conducted to collect demographic and clinical information. Two‐sample t tests, chi‐square tests, and linear regression models were used to compare characteristics (α = 0.05). Analyses were performed in STATA 17.Results: Sixty‐five patients were identified that underwent potassium titanyl phosphate (KTP) transoral laser microsurgery for management of early‐stage LSCC (n = 29) or dysplasia (n = 36). The cohort consisted of 23 Black and 42 White patients. No significant difference was found in age, alcohol or tobacco use, rate of adjuvant radiotherapy, stage of disease, nor insurance status between the 2 groups. White patients underwent more procedures to address initial disease and subsequent recurrent dysplasia on average than Black patients (2.52 vs 1.52, P = .02). This remained true after adjusting for demographic and clinical characteristics and insurance status in a linear regression model. While Black patients were more likely to be lost to follow‐up than White patients (30.4% vs 9.5%, P = .03), the average number of procedures between the groups still differed significantly (2.63 vs 1.56, P = .04) when controlling for those lost to follow‐up.Conclusion: The findings presented here highlight potential inequities that exist for racial minorities at early stages of treatment and in addressing premalignant conditions, which may contribute to the known downstream disparities in laryngeal cancer outcomes.

20 October 2023
Verified
Preprint
Open access
PDF file
TCThomas Cyberski
Thomas Cyberski
NZNicoletta Zipparro
Nicoletta Zipparro
MOMorgan Ottley
Morgan Ottley
ATAlexandra Tate
Alexandra Tate
DMDavid Meltzer
David Meltzer
DADara Adams
Dara Adams
Introduction: Olfactory dysfunction associated with COVID-19 infection is frequently described, but few studies utilize validated, objective tests or a control group. We compared rates of olfactory dysfunction between adults hospitalized with COVID-19 and controls admitted with similar upper respiratory symptoms who were COVID-19-negative. Methods: Hospitalized (general ward) adults with upper respiratory symptoms who tested PCR positive or negative for SARS-CoV-2 completed the objective Brief Smell Identification Test (BSIT; ≥9 correct=normal) and subjective assessments while hospitalized and again at 3 month follow up. Comparison of groups was performed by t test or chi-square test of independence. Results: There were no differences in mean age or gender between groups (n=26 COVID, n=28 control). Both groups demonstrated objective olfactory dysfunction (mean BSIT 7.9 ± 2.8 COVID vs. 8.3 ± 3.2 control, p=0.62). Rates of both objective and subjective dysfunction did not significantly differ between groups. Follow up data at 3 months was limited (n=6 COVID, n=5), but showed 50% olfactory dysfunction in COVID patients compared to 20% in controls. Conclusions: SARS-CoV-2 and other viral illnesses serious enough to cause hospitalization cause olfactory dysfunction. Better understanding of the trajectory of chemosensory recovery will help elucidate the pathophysiology of viral-associated olfactory dysfunction and inform the care of patients suffering from its sequelae.